Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models
(818 nM) than LSCs. AML patient-derived xenograft (PDX) models in NSG-SGM3 mice were treated with MD-265 or an oral MDM2 inhibitor. In PDX models, MD-265 was not toxic and prolonged survival. MD-265 is a potent and specific MDM2 degrader with broad pre-clinical activity and a promising drug candidate for the treatment of leukemias.
Authors
- Megha Ramappan
- Moshe Talpaz (ORCID: https://orcid.org/0000-0003-3361-3981)
- Malathi Kandarpa (ORCID: https://orcid.org/0000-0002-0440-4964)
- Harish Potu
- Avery Polk (ORCID: https://orcid.org/0000-0003-3213-185X)
- Shaomeng Wang (ORCID: https://orcid.org/0000-0002-8782-6950)
- L F Peterson
- Y Liu
Institutions
- University of Michigan (US)
- Michigan Medicine (US)
- Michigan Center for Translational Pathology (US)
Publication Details
- Journal
- Leukemia
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1038/s41375-026-02957-8
- Citations
- 1
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 11.27
Funders
- National Cancer Institute